{"filing":{"accession_number":"0001193125-26-255403","cik":"0001162194","ticker":"LAB","company_name":"STANDARD BIOTOOLS INC.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"lab-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526255403/lab-20260529.htm"},"events":[{"id":3093,"run_id":2698,"accession_number":"0001193125-26-255403","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on the Human Capital Committee's approval of a 500,000 restricted stock unit grant to Sean Mackay, Chief Business Officer, under the 2026 Equity Incentive Plan with a two-year vesting schedule (40% in 2027, 60% in 2028). This is a compensatory arrangement for a named executive officer and falls squarely within exec_compensation. The grant is material as it represents a significant equity award to a senior officer.","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-06-03","items":[{"id":3959,"accession_number":"0001193125-26-255403","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Human Capital Committee's approval of a 500,000 restricted stock unit grant to Sean Mackay, Chief Business Officer, under the 2026 Equity Incentive Plan with a two-year vesting schedule (40% in 2027, 60% in 2028). This is a compensatory arrangement for a named executive officer and falls squarely within exec_compensation. The grant is material as it represents a significant equity award to a senior officer.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:23:17.697914+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3959,"accession_number":"0001193125-26-255403","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Human Capital Committee's approval of a 500,000 restricted stock unit grant to Sean Mackay, Chief Business Officer, under the 2026 Equity Incentive Plan with a two-year vesting schedule (40% in 2027, 60% in 2028). This is a compensatory arrangement for a named executive officer and falls squarely within exec_compensation. The grant is material as it represents a significant equity award to a senior officer.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:23:17.697914+00:00","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-06-03"}]}